Posted by Michael Wonder on 10 Jul 2018
Health Canada approves Gazyva for previously untreated advanced follicular lymphoma
9 July 2018 - Gazyva is the first anti-CD20 treatment in 15 years for the most common subtype of indolent lymphoma.
Roche Canada announced today that Health Canada has approved Gazyva (obinutuzumab), in combination with chemotherapy, followed by Gazyva monotherapy in patients achieving a response, for the treatment of patients with previously untreated stage II bulky (>7 cm), III or IV follicular lymphoma.
The GALLIUM clinical study demonstrated the risk of progression or death was significantly reduced in patients who received a Gazyva-based regimen compared to those who received a Rituxan (rituximab)-based regimen, as an initial (first-line) therapy.
